Union Springs Pharmaceuticals Announces Commercial Launch of MyClyns
Union, KY— Union Springs Pharmaceuticals (USP) today announced the commercial launch of MyClyns First Response:Personal Protection, the only readily accessible, non-alcohol, option that provides an extra layer of protection from potential exposure to Blood Borne Pathogens (BBPs) and Other Potentially Infectious Materials(OPIMs). MyClyns is versatile, convenient and readily accessible spray device that was specifically designed for use in high-stress environments when pathogens render the caregiver most vulnerable to bacterial, viral and fungal exposures. This new product offers first responders, healthcare givers and anyone that comes in to contact with BBPs or OPIMs the option to carry a device with them that can be utilized once a potential exposure has occurred.
"HMS MedicareSim answers the most difficult questions pharmaceutical executives are facing with Medicare Part D," said Dr. Tom Balzer, Chief Scientific Officer at Health Market Science. "Utilizing a system dynamics approach, HMS MedicareSim™ accurately models the actual structure of the market itself and is therefore not constrained by historical performance like traditional statistical-based modeling approaches. The result is a rich and highly interactive simulation environment which empowers executives to plan, manage, and communicate across the enterprise the impact Medicare Part D will have on product revenues and market share."
Pharmaceutical companies using HMS MedicareSim can directly evaluate the impact Medicare Part D will have on prescription volume and market share under numerous market scenarios at a national and regional PDP level. This dynamic simulation model is the first comprehensive planning platform to not only assess the impact Medicare Part D will have on patients, payers, and providers, but also to enable brand managers to plan successful product launches, determine contracting and formulary objectives, and develop winning promotional strategies.
"As a rapidly growing pharmaceutical company, we need to understand how consumers and treating physicians will be impacted by this new federal benefit program," said a VP of Commercial Strategy for a major pharmaceutical company. "HMS MedicareSim enabled us to connect our market research and business plans across the organization into a single planning platform. The approach was especially attractive as it took immediate advantage of our existing market intelligence investments and converted them into an actionable platform upon which we can strategically plan all of our contracting and promotional Part D business initiatives. We now clearly understand what Medicare Part D means to our product portfolio and can plan accordingly."
Dr. Balzer adds, "With the implementation of Medicare Part D, the federal government becomes the single largest healthcare payer in the US marketplace. HMS MedicareSim delivers the enterprise planning capabilities pharmaceutical companies need to make fundamentally sound business decisions in this new market environment."
HMS MedicareSim is licensed on an annual subscription basis and is generally available today.
About the HMS Simulation Platform™
HMS MedicareSim™; is built using a web-based collaborative planning engine named the HMS Simulation Platform™. This innovative platform organizes and compiles disparate forecasts and assumptions, unifying them into a single business planning application. Disparate assumptions and conclusions can now be tested and compared to optimize strategic business plans including sample optimization, sales force sizing, brand management, product launch, and Medicare Part D. The HMS Simulation Platform™; enables teams to rapidly execute a multitude of scenarios in minutes and fully understand the effects various market dynamics will have across all aspects of their business.
About Union Springs Pharmaceuticals
Health Market Science (HMS) is the leading manufacturer of healthcare provider data in the United States. HMS has developed unique technology and expertise to continuously acquire, analyze, and integrate over 2,500 distinct data sources to create and maintain the single most comprehensive and accurate source of healthcare provider information available today. The HMS Provider Master File™ includes detailed reference information for over 4.5 million individual providers and 1.0 million healthcare organizations.
Serving all segments of healthcare, including pharmaceutical manufacturers, biotechs, device manufacturers, payers, providers, and pharmacy chains, HMS is the only company that offers both healthcare-specific data integration services and the reference data that powers them. This unique combination results in dramatically higher data accuracy and reliability, enabling our customers to increase revenues, drive operational efficiencies, achieve regulatory compliance, and maximize market opportunities.
Recognized two consecutive years by the Inc. 500 as one of the fastest growing private companies in the United States, our more than 125 customers include 19 of the top 20 pharmaceutical manufacturers, 10 of the 15 largest device manufacturers, and 2 of the top 5 pharmacy chains. HMS is a privately held company located in King of Prussia, PA. For more information, visit www.healthmarketscience.com.
